Suxamethonium chloride

Suxamethonium chloride

Error creating thumbnail: File missing
Clinical data
Pregnancy category	AU: A US: C (Risk not ruled out)
Routes of administration	Intravenous
ATC code	M03AB01 (WHO)
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Bioavailability	NA
Metabolism	By pseudocholinesterase, to succinylmonocholine and choline
Excretion	Renal (10%)
Identifiers
IUPAC name 2,2'-[(1,4-dioxobutane-1,4-diyl)bis(oxy)]bis (N,N,N-trimethylethanaminium)
CAS Number	306-40-1
PubChem CID	5314
DrugBank	APRD00159
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C14H30N2O4
Molar mass	290.399 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Suxamethonium chloride (also known as succinylcholine, scoline, or colloquially as sux) is a medication widely used in emergency medicine and anesthesia to induce muscle relaxation, usually to make endotracheal intubation possible. Suxamethonium is sold under several trade names such as Anectine, and may be referred to as "sux" for short.

Suxamethonium acts as a depolarizing neuromuscular blocker. It imitates the action of acetylcholine at the neuromuscular junction, acting on muscle type nicotinic receptors, but it is not degraded by acetylcholinesterase but by pseudocholinesterase, a plasma cholinesterase. This hydrolysis by pseudocholinesterase is much slower than that of acetylcholine by acetylcholinesterase.

Chemistry

Suxamethonium is a white crystalline substance, it is odourless; solutions have a pH of about 4, the dihydrate melts about 160^oC, the anhydrous melts at about 190^oC; it is highly soluble in water (1 gram in about 1 mL), soluble in alcohol (1 gram in about 350 mL), slightly soluble in chloroform, and practically insoluble in ether. Suxamethonium is a hygroscopic compound. The compound consists of two acetylcholine molecules that are linked by their acetyl groups.

Effects

There are two phases to the blocking effect of suxamethonium; phase 1 block and phase 2 block, of which the phase 2 block is the principal paralytic effect.

Phase 1 block

The first is due to the prolonged stimulation of the acetylcholine receptor results first in disorganized muscle contractions (fasciculations, considered to be a side effect as mentioned below), as the acetylcholine receptors are stimulated. On stimulation, the acetylcholine receptor becomes a general ion channel, resulting in a high flux of potassium out of the cell, and of sodium into the cell, generating an endplate potential less than the action potential. After this initial firing, the cell enters a refractory period.

Phase 2 block

On continued stimulation, the acetylcholine receptors become desensitised and close. This means that new acetylcholine signals do not cause an action potential; and the continued binding of suxamethonium is ignored. This is the principal paralytic effect of suxamethonium, and wears off as the suxamethonium is degraded, and the acetylcholine receptors return to their normal configuration.

Medical uses

Its medical uses are limited to short-term muscle relaxation in anesthesia and intensive care, usually for facilitation of endotracheal intubation. Despite its many undesired effects on the circulatory system and skeletal muscles (including malignant hyperthermia, a rare but life-threatening disease), it is perennially popular in emergency medicine because it arguably has the fastest onset and shortest duration of action of all muscle relaxants. Both are major points of consideration in the context of trauma care, where paralysis must be induced very quickly and the use of a longer-acting agent might mask the presence of a neurological deficit.

Suxamethonium is quickly degraded by plasma cholinesterase and the duration of effect is usually in the range of a few minutes. When plasma levels of cholinesterase are greatly diminished or an atypical form of cholinesterase is present (an otherwise harmless inherited disorder), paralysis may last much longer.

Side effects

Side effects include fasciculations, muscle pains, acute rhabdomyolysis with hyperkalemia, transient ocular hypertension, constipation and changes in cardiac rhythm including bradycardia, cardiac arrest, and ventricular dysrhythmias. In children with unrecognized neuromuscular diseases, a single injection of suxamethonium can lead to massive release of potassium from skeletal muscles with cardiac arrest.

Suxamethonium does not produce unconsciousness or anesthesia, and its effects may cause considerable psychological distress while simultaneously making it impossible for a patient to communicate. For these reasons, administration of the drug to a conscious patient is strongly contraindicated, except in necessary emergency situations.

Hyperkalemia

The side effect of hyperkalaemia is because the acetylcholine receptor is propped open, allowing continued flow of potassium ions into the extracellular fluid. A typical increase of potassium ion serum concentration on administration of suxamethonium is 0.5 mmol per litre, whereas the normal range of potassium is 3.5 to 5 mmol per litre, i.e. a significant increase.

Hyperkalemia, in turn, results in other side-effects of ventricular fibrillation due to reduced to action potential initiation in the heart.

Death

This drug has occasionally been used as a paralyzing agent for executions by lethal injection, although pancuronium bromide is the preferred agent today because of its longer duration of effect and its absence of fasciculations as a side effect. It has also allegedly been used for murder. For instance, suxamethonium is the drug that is suspected to have been used to murder Nevada State Controller Kathy Augustine.

See also

• Malignant hyperthermia, a rare and fatal side effect of suxamethonium.
• Anesthetics